As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Coya Therapeutics, Inc. The largest reported stake is Dr. Reddy's Laboratories, Inc.'s, at 9.7%. 4 filings are on record since January 28, 2026 (Schedule 13G, March 12, 2026).
Sell to companies like Coya Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Orin Hirschman · Sole voting: 764,679 · Shared voting: 0 · Sole dispositive: 764,679 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-07-27
- · Reporting person: Dr. Reddy's Laboratories, Inc. · Sole voting: 2,272,727 · Shared voting: 0 · Sole dispositive: 2,272,727 · Shared dispositive: 0 · SCHEDULE 13G, 2026-03-12
- · Reporting person: The Vanguard Group · Sole voting: 0 · Shared voting: 117,776 · Sole dispositive: 0 · Shared dispositive: 899,140 · SCHEDULE 13G/A, 2026-01-30
- · Holder: Orin Hirschman · Percent: 5.3% · SCHEDULE 13G/A
Coya Therapeutics, Inc. has 4 Schedule 13D or 13G filings on record since 2026-01-28. 1 holder's latest filing reports 5% or more of common stock, $0.0001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Dr. Reddy's Laboratories, Inc. | 9.7% | 2,272,727 | SCHEDULE 13G, 2026-03-12 | 2026-01-30 |
| The Vanguard Group | 4.29% | 899,140 | SCHEDULE 13G/A, 2026-01-30 | 2025-12-31 |
| 3.3% | 764,679 | SCHEDULE 13G/A, 2026-07-27 | 2026-06-30 |
Holding shares or following this stake? See who's behind Coya Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Coya Therapeutics, Inc. and the records around it.
Coya Therapeutics, Inc. elsewhere on the record
- Leadership changes Aug 2026
- Who owns it
Companies that share a holder
- Orin Hirschman also filed stake reports on 46 other companies: ASPEN AEROGELS, INC. (Oct 2026), Bionano Genomics, Inc. (Oct 2026), FENNEC PHARMACEUTICALS INC. (Oct 2026)
- The Vanguard Group also filed stake reports on 2384 other companies: BellRing Brands, Inc. (Sep 2026), CAL-MAINE FOODS INC (Sep 2026), FTAI Aviation Ltd. (Sep 2026)
Watch Coya Therapeutics, Inc.
Get an email when Coya Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Coya Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Coya Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Coya Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
6 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Dr. Reddy's Laboratories, Inc. | 2,272,727 | 0 | 2,272,727 | 0 | SCHEDULE 13G, 2026-03-12 |
| Dr. Reddy's Laboratories SA | 2,272,727 | 0 | 2,272,727 | 0 | SCHEDULE 13G, 2026-03-12 |
| Dr. Reddy's Laboratories Limited | 2,272,727 | 0 | 2,272,727 | 0 | SCHEDULE 13G, 2026-03-12 |
| The Vanguard Group | 0 | 117,776 | 0 | 899,140 | SCHEDULE 13G/A, 2026-01-30 |
| Orin Hirschman | 764,679 | 0 | 764,679 | 0 | SCHEDULE 13G/A, 2026-07-27 |
| AIGH Capital Management LLC | 631,912 | 0 | 631,912 | 0 | SCHEDULE 13G/A, 2026-07-27 |
The latest filing identifies Coya Therapeutics, Inc. by CUSIP 22407B108 and gives its principal executive office as 5850 San Felipe St., Suite 500, Houston, TX 77057 (SCHEDULE 13G/A, 2026-07-27).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-01-28 | Orin Hirschman | 5.3% | SCHEDULE 13G/A |
| 2026-01-30 | The Vanguard Group | 4.29% | SCHEDULE 13G/A |
| 2026-03-12 | Dr. Reddy's Laboratories, Inc. | 9.7% | SCHEDULE 13G |
| 2026-07-27 | Orin Hirschman | 3.3% | SCHEDULE 13G/A |
Questions about who owns Coya Therapeutics, Inc.
Who owns Coya Therapeutics, Inc.?
On this page, one holder's latest ownership filing reports 5% or more of Coya Therapeutics, Inc.: Dr. Reddy's Laboratories, Inc. (9.7%, Schedule 13G, filed 2026-03-12).
When did Dr. Reddy's Laboratories, Inc. buy into Coya Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Dr. Reddy's Laboratories, Inc. on this page is the Schedule 13G, filed 2026-03-12, reporting 9.7%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 4 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Coya Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 7, 2026 | Leadership change: Mark H. Pavao appointed | — | Leadership changes | Source |
| April 2, 2026 | Leadership change: Howard Berman departs, Executive Chairman, and 1 more | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Coya Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.